Ex-Vivo Reversion of Platelet Inhibition Induced by Prasugrel

Completed

• Conditions: Acquired Platelet Disorder
• Interventions: Other: Ex vivo addition of normal platelet rich plasma to prasugrel-treated platelet rich plasma

• Registration Number: NCT01839968
• Lead Sponsor: University Hospital, Geneva

Brief Summary

The purpose of this ex-vivo study is to estimate the optimal platelet quantity necessary to reverse the antiplatelet effects of prasugrel.

Detailed Description

Not available

Study Timeline

• Study Start: 2011-09
• Study First Submitted: 2013-04-22
• Study First Submitted QC: 2013-04-24
• Study First Posted: 2013-04-25
• Primary Completion: 2013-12
• Study Completion: 2014-01
• Status Verified: 2014-08
• Last Update Submitted: 2014-08-18
• Last Update Posted: 2014-08-19

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 32

Inclusion Criteria

• Acute coronary syndrome
• Prasugrel loading dose 6-24h before inclusion

Exclusion Criteria

• Clopidogrel loading dose
• GPIIbIIIa use within 10 days before inclusion
• Known congenital thrombopathy and/or congenital coagulation defect

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Study patients	Ex vivo addition of normal platelet rich plasma to prasugrel-treated platelet rich plasma	Acute coronary syndrome patients with a recent loading dose of prasugrel (6-24h)

Primary Outcome Measures

Name	Time	Method
Platelet reactivity assessed by light transmittance aggregometry (LTA) after ex-vivo normal platelet addition	within the first 6-24 hours after antiplatelet drug loading dose

Trial Locations

Locations (1)

University Hospital of Geneva; 🇨🇭 Geneva, GE, Switzerland